Critics of Australia's medical device regulation argue that the current system is fundamentally flawed, creating a 'race to the bottom' where commercial interests are prioritized over patient safety. They contend that the reliance on overseas approvals and the lack of mandatory, rigorous local testing for many high-risk devices allow manufacturers to bypass the scrutiny that is rightfully expected for products implanted into the human body. This, they argue, leaves the Australian public exposed to unnecessary and preventable harm.
The accountability-focused view highlights that the current regulatory gaps are not merely administrative oversights but systemic failures that have persisted for years. By failing to act decisively on warnings from other jurisdictions or ignoring early signals of device failure, the regulator has allowed products with questionable safety profiles to remain in use. Critics point to the high number of annual hospitalisations linked to medical devices as clear evidence that the existing post-market monitoring is insufficient to protect the community.
For these advocates, the solution lies in a complete overhaul of the approval process, including mandatory local clinical trials for high-risk implants and a fully transparent, publicly accessible registry for all medical devices. They argue that patients have a right to know the risks associated with the technology they are receiving and that the current lack of transparency prevents informed consent. Without stronger, more proactive regulation, they warn that the cycle of injury and subsequent litigation will continue, ultimately undermining public trust in the entire healthcare system.